archiviert
In brief: Buyer's accounting for royalties and milestones payable to a seller in a business combinationAcquisitions and divestitures have been headline news in the pharmaceutical and life sciences industry lately. With expiring patents on blockbuster products and downward pricing pressure, many companies have increased their M&A activity and turned to acquisitions to expand research pipelines in order to fuel innovation.
Themen
Weiterlesen mit einem PwC Plus-Abonnement
- qualitätsgesicherte Quellen
- tägliche Updates
- vollständige Filterfunktion von Artikeln
- Verteilung via anpassbarem Alert
© 2017 - 2025 PwC. All rights reserved. PwC refers to the PwC network and/or one or more of its member firms, each of which is a separate legal entity. Please see www.pwc.com/structure for further details. Portions of this program may use third-party open source components governed by the respective open source license terms.
This website contains copyright material of the IFRS® Foundation in respect of which all rights are reserved. Reproduced by PwC with the permission of the IFRS Foundation. No permission granted to third parties to reproduce or distribute. For full access to IFRS Standards and the work of the IFRS Foundation please visit www.ifrs.org.